AXGN news today — last 24 hours, 7 days, 30 days

AXOGEN INC (AXGN) — News & AI sentiment

AXOGEN INC (AXGN) news roundup. 1 story in the past week, 14 over 30 days. Average 30-day sentiment is 57.4/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 4 sales totalling $4.7M — net selling of $4.7M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

7d stories

avg sentiment 34/100

30d stories

avg sentiment 57.4/100

Insider net (90d)

$4.7M

0 buys · 4 sells

Congress (90d)

0 buys · 0 sells

AXGN news in the last 24 hours, 7 days, 30 days and 90 days

How much AXGN coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time window	AXGN stories	Avg AI sentiment	Read
Last 24 hours	0	—	no coverage
Last 7 days	1	34/100	AXGN headlines →
Last 30 days	14	57.4/100	AXGN headlines →
Last 90 days	34	54.5/100	AXGN headlines →

Latest stories on AXGN

AxoGen price target lowered to $50 from $55 at Barclays

The Fly34 · bearishanalyst

5d ago

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

Business Insider50 · neutralgeneral

Oct 14

Axogen, Inc. to Report Third Quarter 2026 Financial Results on October 28, 2026

GlobeNewswire50 · neutralgeneral

Oct 14

AxoGen stock initiated at Buy by BofA on growth outlook

Investing.com Analyst Ratings64 · neutralanalyst

Oct 12

AxoGen initiated with a Buy at BofA

The Fly63 · neutralanalyst

Oct 12

AxoGen initiated with an Overweight at Barclays

The Fly61 · neutralanalyst

Oct 6

AxoGen should be bought on weakness, says Lake Street

The Fly63 · neutralanalyst

Oct 5

AxoGen Acquires BioCircuit, Expands Peripheral Nerve Portfolio

TipRanks63 · neutralm&a

Oct 1

Axogen, Inc. (AXGN) files 8-K

SEC 8-K50 · neutralgeneral

Oct 1

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

GlobeNewswire62 · neutralm&a

Oct 1

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

Business Insider62 · neutralm&a

Oct 1

Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair

StockTitan62 · neutralm&a

Oct 1

3 Emerging Biotech Stocks With Significant Upside Potential

MarketBeat58 · neutralanalyst

Sep 30

Truist reiterates Buy on AxoGen stock after Aetna coverage win

Investing.com Analyst Ratings61 · neutralanalyst

Sep 29

AxoGen price target raised to $53 from $48 at Raymond James

The Fly61 · neutralanalyst

Sep 25

Axogen deepens nerve repair portfolio through $200m BioCircuit takeover

Yahoo Finance63 · neutralm&a

Sep 11

8-K/A - Axogen, Inc. (AXGN) files 8-K

SEC 8-K50 · neutralgeneral

Sep 10

Axogen Raises $200 Million to Fund BioCircuit Buyout Focused on Sutureless Nerve Repair

Yahoo Finance24 · bearishgeneral

Sep 10

Axogen, Inc. (AXGN) M&A Call Transcript

Seeking Alpha50 · neutralm&a

Sep 10

Axogen stock falls as $208.7M offering dilutes shareholders

Investing.com Markets24 · bearishgeneral

Sep 10

Why is Axogen stock sliding today?

Investing.com Markets48 · neutralgeneral

Sep 10

Axogen to buy BioCircuit Technologies for $200M

Seeking Alpha62 · neutralm&a

Sep 10

AxoGen to Acquire BioCircuit, Expanding Nerve Repair Portfolio

TipRanks62 · neutralm&a

Sep 10

AxoGen 4.91M share Secondary priced at $42.50

The Fly28 · bearishgeneral

Sep 10

Axogen to Buy NerveTape Maker BioCircuit for $200 Million

MarketWatch62 · neutralm&a

Sep 10